公开(公告)号：EP2609081A1

公开(公告)日：2013-07-03

申请号：EP11752398.5

申请日：2011-08-22

申请人： Amgen Inc.

发明人： ASHTON, Kate ,  BARTBERGER, Michael David ,  BO, Yunxin ,  BRYAN, Marian C. ,  CROGHAN, Michael ,  FOTSCH, Christopher Harold ,  HALE, Clarence Henderson ,  KUNZ, Roxanne Kay ,  LIU, Longbin ,  NISHIMURA, Nobuko ,  NORMAN, Mark H. ,  PENNINGTON, Lewis Dale ,  POON, Steve Fong ,  STEC, Markian Myroslaw ,  ST. JEAN, David, Joseph, Jr. ,  TAMAYO, Nuria A. ,  TEGLEY, Christopher Michael ,  YANG, Kevin Chao

IPC分类号： C07D213/30 ,  C07D213/71 ,  C07D213/74 ,  C07D231/18 ,  C07D239/42 ,  C07D241/04 ,  C07D277/36 ,  C07D333/34 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D491/08 ,  C07D498/08

CPC分类号： C07D333/34 ,  C07C317/22 ,  C07D213/30 ,  C07D213/32 ,  C07D213/71 ,  C07D213/72 ,  C07D213/74 ,  C07D231/18 ,  C07D239/42 ,  C07D241/04 ,  C07D277/36 ,  C07D285/135 ,  C07D295/26 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D491/08 ,  C07D498/08

摘要： The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.